Two patented dietary supplement ingredients from Gateway Health Alliances increased GLP-1 levels, reduced body weight, and improved metabolic biomarkers in a 12-week clinical study.
In a randomized, double-blind, placebo-controlled study involving 90 overweight or obese subjects, two Gateway products — Dyglomera and CQR-300 — significantly increased endogenous GLP-1 levels, a peptide hormone that stimulates insulin release in response to meals. Participants were randomly assigned to one of three groups: a placebo group, a group receiving 300 mg of CQR 300, and a group taking 400 mg of Dyglomera daily.
According to Gateway, the ingredients elevate GLP-1 through the inhibition of dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for breaking down GLP-1. As a result, GLP-1 remains in the body longer at significantly higher levels, actively enhancing its effects on glucose regulation and appetite control. In the study, both extracts significantly inhibited DPP-4 activity over the course of the study. DDP-4 levels decreased by 59% in the Dyglomera group and 54% in the CQR-300 group, while the placebo group experienced a 129% increase in DPP-4 activity.
By week 12, participants in the Dyglomera group experienced an average body weight reduction of 17%, while those in the CQR-300 group had a 14% reduction. Those in the placebo group experienced a 1.67% reduction in body weight.
CQR-300, a patented extract powder of Cissus quadrangularis, comes from a plant native to India, Asia and West Africa. Dyglomera is a standardized powder prepared by extracting D. glomerata fruit pods with aqueous ethanol followed by concentration and drying.